Check back at 8:30 a.m. ET for the results
DUBLIN, January 24, 2022–(BUSINESS WIRE)–The "Drug Abuse Testing Market, Size, Global Forecast 2022-2027, Industry Trends, Impact of COVID-19, Opportunity Company Analysis" report has been added to ResearchAndMarkets.com's offering.
This report studies the global drug abuse testing market and provides an all-encompassing analysis of the key growth drivers and challenges, market trends, key players and their projections for the future. The global drug abuse testing market is projected to reach US$ 5.93 Billion by 2027, from $4.02 Billion in 2021.
Dragerwerk AG & Co. KGAA
Quest Diagnostics Incorporated
There has been a rise in drug abuse testing in recent years. Drug abuse testing is conducted for medical purposes and legal causes, such as workplace drug testing. Medical drug testing is often performed in a hospital clinical laboratory to screen the appearance of any drug in the urine of a person admitted with a suspicion of a drug overdose. Medical drug testing is conducted in a hospital laboratory by using an automated analyzer. These analyzers are FDA approved immunoassays in most of the cases. Due to the increasing interest of the companies in the Drug of abuse testing industry, the key players in the market are acquiring or collaborating with other firms to attain a more prominent share in drug of abuse testing market.
Urine Testing has the Highest Market Share
Urine testing is the most preferred sample type used for drug abuse testing because of its low cost. Urine testing has the highest revenue and is expected to maintain its position in the future. Drug testing is now increasingly used by employers, sports organizations, forensic purposes, and several other applications. Hair as a specimen is also becoming a more effective way to test long-term drug use. Hair and Blood sample type compete very closely to grab the maximum share of the pie. Besides, technological advancements in drug screening/testing devices and stringent government regulations mandating drug screening boost the market growth.
Worldwide Drug Abuse Testing Market Size was US$ 4.02 Billion in 2021
The Drug of abuse testing industry includes Analyzers, Rapid Testing Devices, Consumables and Laboratory Services. Amongst this, Laboratory service are used most of the time as its convenient and inexpensive method of testing Drugs for screening large numbers of samples in a variety of matrices compared to other methods. The laboratory service market size is projected to grow during the forecast period.
Drug Abuse Testing Market likely to grow at a CAGR of 6.7% during 2021- 2027
Based on Setting System, the most considerable drug testing is done in the criminal justice system and employment. Drug of abuse Professional POC tests helps in reducing the time between diagnosis and treatment of a disease. The high growth rate is attributed to rising drug and alcohol consumption, government funding in global industries, stringent laws mandating drug and alcohol testing, regulatory approvals, and new product and service launches.
North America has the most Dominant Market
North America is the world's most dominant drug abuse testing market due to the increase in the usage of drugs. Testing drugs is an essential part of every organization, transportation, corporate sector, and many others in the United States and Canada. European regions drug abuse testing industry is also growing year on year. The anti-drug devices drive in high demand due to increased road accidents by alcoholic and drunk people. Asia-Pacific countries like China, India, Singapore, and Japan are experiencing a growth in their drug of abuse testing market, primarily due to the government stringent rules and regulations.
The Impact of the COVID-19 Pandemic on the Drug Abuse Testing Industry
Since 2019, the social and economic restrictions due to the coronavirus pandemic have seriously impacted health and social fields. Forced quarantine and isolation during COVID-19 have affected the behavior of drug abusers. Fingerprint-based drug testing is a new concept that has gained popularity in recent years. The COVID-19 pandemic has made it hard to perform drug testing in labs, hospitals, and other facilities due to the possibility of transmission of the infection.
Key Topics Covered:
2. Research Methodology
3. Executive Summary
4. Market Dynamics
4.1 Growth Drivers
5. Drug of Abuse Testing Market
6. Market Share – Drug of Abuse Testing Market
7. Product & Service – Drug of Abuse Testing Market
8. Testing Type – Drug of Abuse Testing Market
9. Setting Type – Drug of Abuse Testing Market
10. End Users – Drug of Abuse Testing Market
11. Regions – Drug of Abuse Testing Market
12. Porters Five Forces
13. Company Analysis
For more information about this report visit https://www.researchandmarkets.com/r/fa2mt5
View source version on businesswire.com: https://www.businesswire.com/news/home/20220124005514/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Let's take a quick look at how Vaxart's project might be a game-changer. There are two things in Vaxart's favor regarding the chances of its pill being a pandemic-ending tool. Unlike the jabs produced by Pfizer and Moderna, Vaxart's oral tablet doesn't require skilled staff or syringes to administer, nor does it require specialized refrigerators to keep the vaccine stable.
The Biden administration is issuing 400 million free nonsurgical N95 masks to stop the spread of COVID-19.
The road to FDA approval can be long, and in the case of COVID-19 vaccines, there is no time for delays and no room for error. One company that has come to understand this very well is Novavax (NASDAQ: NVAX). Since 2020, the company has been developing a vaccine to help prevent and fight the impact of COVID-19.
Short-staffed employers are pressuring workers to stay on the job while feeling sick or with COVID-19. CDC guidance and testing disparities aren't helping.
Sierra Oncology reported a late-stage win Tuesday for a bone cancer drug it acquired at a discount — and the biotech stock catapulted.
Vaccinex Inc (NASDAQ: VCNX) shares are gaining after the Company reported interim response data in the Phase Ib segment of the KEYNOTE-B84 study. The trial is evaluating Vaccinex's pepinemab combined with Merck & Co Inc's (NYSE: MRK) Keytruda (pembrolizumab) in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). Among the three patients enrolled in the safety segment of the study, two patients experienced a complete response (CR). Biomarker analysis revealed that tumors in
Publix, Walgreens, Walmart pharmacies are working with federal officials to offer free N95 masks in varying sizes at GA stores this week.
Even though the world has been dealing with the COVID-19 pandemic for nearly two years, we're still learning about the virus and how it can affect our bodies. One area of understanding that has been particularly difficult to grasp has been the wide range of symptoms the virus can cause and how some can stick around long after recovery. Now, a new study has found that one symptom is having a long-term effect on about half of people who have caught COVID. Read on to see which ailment could be stic
The Omicron variant has been spreading so quickly that it has caused a surge of new COVID cases in the U.S. much like the previously dominant Delta variant. But unlike Delta, Omicron also appears to be causing a much higher number of breakthrough infections. Doctors have confirmed that both unvaccinated and fully vaccinated people can catch this variant, although they might experience vastly different illnesses. In fact, there are COVID symptoms that are much more likely to occur in vaccinated p
Early in the pandemic, Ryan Wilson was careful to take precautions — wearing a mask, not really socializing, doing more of his shopping online. The 38-year-old father and seafood butcher from Casselberry, Florida, says he relaxed a bit after getting vaccinated last year.
The U.S. Navy announced Wednesday it has discharged 45 service members for refusing the COVID-19 vaccine, including 23 active-duty sailors.Why it matters: This is the first time the Navy has announced that it's kicked out sailors for not getting inoculated against the coronavirus since the military's Nov. 28 vaccine mandate expired, per the Navy Times.Stay on top of the latest market trends and economic insights with Axios Markets. Subscribe for freeThe Army is the only remaining service yet to
The FDA has approved Immunocore Holdings plc (NASDAQ: IMCR) (tebentafusp-tebn) for HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma (mUM). Marketed as Kimmtrak, approval highlighting a series of firsts: First TCR therapeutic to receive FDA approval, First bispecific T cell engager to receive FDA approval to treat a solid tumor. The first and only therapy for unresectable or metastatic uveal melanoma to be approved by the FDA. Related: Immunocore Tebentafusp Show
The top public health authorities in the Biden administration denounced misinformation about the coronavirus vaccines following an anti-vaccine rally in Washington, D.C., over the weekend and a falsehood-laden segment on Fox News on Tuesday night that has been widely shared on social media.
(Bloomberg) — Hong Kong is shortening its quarantine period for inbound travelers to 14 days, Chief Executive Carrie Lam said. The United Arab Emirates ranked first in the list of best places to be as omicron spreads. Most Read from BloombergPowell Backs March Liftoff, Won’t Rule Out Hike Every MeetingA Nor’easter Approaching New York Risks Becoming a Bomb CycloneApple to Rival Square by Turning iPhones Into Payment TerminalsStocks Halt Rally as Bond Yields Spike After Fed: Markets WrapAstronom
"I refuse to watch my patients die because of absolute chaos that could otherwise be avoided, while, sadly, we are told to keep quiet as the ship we’re on sinks."
There's a lot unknow about new variant, including whether it evades vaccines better or causes more severe disease. Here's what we do know.
Gregory Zuckerman, author of ‘A Shot to Save the World’, joins Yahoo Finance's Editor-in-Chief, Andy Serwer, for a discussion about what COVID-19 will look like in the future.
Few things inspire as much passion in the Republican base these days as alternative and often-unproven coronavirus treatments – even as many in the party continue to shun the most proven-effective treatment: vaccination. There has thus been a premium on politicians promoting these treatments or at least decrying scientists and government officials who question or reject their use. In 2020, the prime example was hydroxychloroquine. In 2021, it was ivermectin. And early in 2022, it's monoclonal an
A Boston hospital is defending itself after a man's family claimed he was denied a new heart for refusing to be vaccinated against COVID-19, saying most transplant programs around the country set similar requirements to improve patients’ chances of survival. The family of D.J. Ferguson said in a crowdfunding appeal this week that officials at Brigham and Women’s Hospital told the 31-year-old father of two that he was ineligible for the procedure because he hasn’t been vaccinated against the coronavirus. D.J.'s mother, Tracey Ferguson, insists that her son isn't against vaccinations, noting he's had other immunizations in the past.
China's "zero-COVID" stance has put it at odds with the rest of the world and is exacting a mounting economic toll, but an exit strategy remains elusive as authorities worry about the ability of the healthcare system to cope and adapt to new strains. Chinese medical experts believed last year that higher vaccination rates would eventually allow China to relax tough rules on movement and testing as infection rates slow elsewhere. While some analysts have branded China's approach as "unsustainable", many local health experts – and some from overseas – say the country has no choice but to continue given its less developed health system.